



Uplizna in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

NEUROLOGY · NMOSD (AQP4-IGG+)

The clinical situation

Uplizna (inebilizumab-cdon) is an FDA-approved anti-CD19 B-cell-depleting monoclonal antibody for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive, manufactured by Amgen (Horizon). Dosing is an IV infusion on Day 1 and Day 15, then every six months. Eligibility requires confirmed AQP4-IgG seropositivity, documented NMOSD criteria, and a pre-treatment screening bundle (hepatitis B, tuberculosis, immunoglobulins, vaccinations). Administration must occur at a licensed infusion centre capable of managing infusion reactions.

The pathway, 6 steps

- 1 Consultation with neurology.** AQP4-IgG confirmation, NMOSD diagnosis, and pre-treatment screening (HBV, TB, Ig, vaccinations) documented.
- 2 Infusion facility identification.** A UAE-licensed infusion centre able to administer monoclonal antibodies and manage reactions.
- 3 MoHAP named-patient application.** Physician files clinical letter, patient identifier, infusion-facility plan, and product details (DoH/DHA as applicable).
- 4 US-side sourcing.** Reserve Meds coordinates through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Cold-chain shipment.** Uplizna ships at 2–8°C with continuous temperature monitoring.
- 6 Arrival & infusion.** Day 1 and Day 15 loading doses, then six-monthly maintenance.

Indicative economics

Reference US cash-pay range: USD 400,000–500,000 annualised (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first infusion, once cohort intake opens — screening lead-time may extend this. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP (or DoH/DHA) review, keyed to the AQP4-IgG-positive NMOSD rationale. **Logistics.** 2–8°C cold-chain coordination to the licensed infusion centre. **Concierge case lead.** Named point of contact across the induction and biannual-maintenance cadence. **We are a coordinator** — not the prescriber, not the dispensing pharmacy, not the infusion centre. All clinical decisions remain with your treating neurologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Uplizna × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/uplizna-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team